ProCE Banner Activity

KEYNOTE-826: Subgroup Analysis of Pembrolizumab + Chemotherapy ± Bevacizumab in Persistent, Recurrent, or Metastatic Cervical Cancer

Slideset Download
Conference Coverage
Pembrolizumab + chemotherapy ± bevacizumab prolonged PFS and OS vs placebo + chemotherapy ± bevacizumab in key patient populations, including those defined by bevacizumab use, histology, platinum use, and prior chemoradiotherapy.

Released: June 09, 2022

Expiration: June 08, 2023

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

BMS

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation

Seagen and Genmab